A long-form section, not a sales pitch. The FDA framework, in plain English. What U.S. clinics are, and are not, actually offering. Trial-vs-treatment as a real decision, not a tagline. Insurance and tax treatment, honestly.
Prefer to watch?
Short on time? The video makes the same honest case this section does: the FDA isn't broken, it's calibrated for a different question than the one you're asking. Keep scrolling for the full version.
Read in order, this section moves from regulation → the U.S. landscape → trial alternatives → safety → paying for it. Each article holds up alone if you only have time for one.
Most clinics open this conversation with a complaint about the FDA. We won't, because it isn't accurate. The FDA's framework for cell and tissue products is: by global standards: careful, sober, and well-considered. It is also calibrated to a very specific question: under what conditions may a company sell a new biological product, at scale, to American patients? That question is not the same as the one most cell-therapy patients are actually asking, which is closer to: can a physician use a well-characterized cell preparation, in a single supervised procedure, in my body, today?
The first question takes a decade and several hundred million dollars to answer for each indication. The second question is, in many jurisdictions, answerable within a clinic licensing framework, supervised by national health authorities, with the physician (rather than a manufacturer) as the regulated actor. That is the framework Mexico's COFEPRIS uses; it is the framework most of Western Europe uses; it is not a loophole, and we will not describe it that way.
This section is the part of our library that walks through that distinction, slowly. It is the most-referenced section by the people who actually read all the way through. We wrote it for the patient who has been told, by a U.S. doctor they trust, that there is "nothing more to do": and who wants to understand, before traveling anywhere, what they would and would not be agreeing to by treating abroad.
You will not find, in the next five articles, the argument that the FDA is conspiring against you. You will find the argument that the FDA is doing one job, that the job it is doing is not the one your situation may need done, and that the most honest version of cell therapy today happens to live outside of the U.S. regulatory perimeter for reasons that are unsexy and bureaucratic, not nefarious.
The FDA's 21 CFR 1271 doesn't ban cell therapy, it carves out a corridor inside which a cell preparation does not require Investigational New Drug authorization. Four conditions, read together. Cross any one of them, and you are in drug-approval territory: ten years and hundreds of millions of dollars per indication.
You may centrifuge cells. You may wash them. You may not grow them in culture, expand them, freeze and thaw them, or change what they do. The line lives at 21 CFR 1271.3(f) "minimal manipulation."
The cells must be used for the same biological function they performed in the donor. Bone graft → bone repair, yes. Fat-derived stromal cells → joint cartilage, no. The latter is the most common protocol abroad, and the most common reason U.S. clinics get shut down.
The cells must stand alone. A saline carrier or a cryoprotectant is fine. Mix in a growth factor, a steroid, an exosome cocktail, or a synthetic scaffold, and the result is a combination product, evaluated as a drug.
If the cells act on the whole body or stay biologically active, they must come from the patient, or a first- or second-degree blood relative. Allogeneic preparations given systemically, including the umbilical-cord MSCs that underpin most of the modern evidence base, have no §361 path.
The corollary, not the conspiracy. A clinic that wants to use cultured allogeneic umbilical-cord MSCs to modulate inflammation in a joint, a protocol with strong peer-reviewed evidence: fails three of the four prongs at once, and must either run a multi-year clinical trial under an IND, wait for someone else to do so, or operate outside the U.S. perimeter. There is no quiet way through.
The rules above force a particular kind of workaround, but they do not police the word on the brochure. A U.S. clinic can legally call almost anything a "stem-cell therapy" as long as the underlying product is registered under the right HCT/P pathway. What ends up in the syringe is often something more modest.
The honest version of the U.S. menu, then: a small fraction of clinics use viable autologous cells under one of the §361 carve-outs; a smaller fraction operates a real IND; the rest are selling something that has been frozen, sterilized, fractionated, or relabeled, with the word stem cell doing more work than the contents of the vial.
Each was edited to be readable on its own. Read in order, they construct an argument; read individually, they answer a specific question. Each article ends with the same "what this article cannot tell you" coda we use throughout the library.
A walk through 21 CFR 1271 for the patient. The four rules we just diagrammed, with the case law and enforcement history behind each. Why the framework looks the way it does: its origins in the 2001 HCT/P rulemaking, the 2017 guidance documents, and the Regenerative Sciences and US Stem Cell cases that defined "minimal manipulation" in court.
A factual map. Why nearly every domestic "stem cell" clinic offers the same three preparations: autologous PRP, bone-marrow aspirate concentrate, and stromal vascular fraction, and what each one is, biologically. The places the line gets drawn well (PRP for tendinopathy) and the places it gets drawn badly (SVF for systemic inflammation). Not a takedown. A topography.
The article we wish more patients read first. A decision aid for the person who has just discovered there are U.S. trials for their condition and is trying to figure out whether to wait for one, apply to one, or pay for treatment elsewhere now. Time costs, eligibility math, and the way randomization actually works when half of you gets a saline infusion.
The question we get asked first, written for the spouse rather than the patient. The honest answer depends on the procedure, the country, the facility, and the way the trip itself is organized, and those are four different conversations. What separates a legitimate cross-border procedure from the cautionary tales. The infection-control questions worth asking, by name.
U.S. commercial insurance does not cover cell therapy in Mexico, and most plans do not cover cell therapy in the U.S. either, for the indications discussed here. What HSA and FSA can and cannot do, with a Letter of Medical Necessity from your U.S. physician or from us on request. Medical-deduction math for the itemizer under IRS §213. What we hand you, what you assemble yourself, and where the real reimbursement levers live.
It isn't. It is slow, conservative, and structured around a question that does not match every patient situation. Those are three different things.
The library is research-grade. Patient stories live, with permission and disclosure, on a separate page. They do not belong in an explanation of regulation.
If a section on regulation could be reduced to ten minutes, the regulation wouldn't be doing much. It can be read in forty-two. That seems like a fair trade.
Most of them are right not to. The article on the U.S. landscape spells out, by preparation, which ones are well-evidenced and which are not.
Mexico is different, in ways that make this kind of therapy more accessible right now. That is the specific claim. Section 2 →
If you are going to read one article in this section, read this one, every other article in the library leans on it, and most of the questions we get on consult calls trace back to one of the four rules it explains.